Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.

The extra-light blonde highlights Jennifer Lawrence wore at the Golden Globes brighten the face and create a naturally ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Apple will lean on Google to help finish its bungled attempts to smarten up its virtual assistant Siri and bring other ...

BCCL IPO subscription period runs until January 13, with a potential listing price of ₹33.6, reflecting a 46.09% premium over ...

Dean Richards, entertainment reporter for WGN, joins Bob Sirott to provide the latest news in entertainment. Bob and Dean ...

From national broadcasters and major newspapers to specialist health titles and online platforms, 2025 has been another ...

Highlights: BCCL smashes 100x subscription! Should you bet on India’s 'Black Gold' monopoly or avoid the hype?

BCCL IPO price band has been fixed at ₹21-23 per share. Shares of the PSU company will list on BSE and NSE later this week at ...

Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...